Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment [PDF]
, 1997 Neuropsychiatric side effects often complicate anti-Parkinsonian therapy and pose a significant problem in the optimal management of idiopathic Parkinson's disease.
Abbott, R.J. +6 more
core +2 more sources
Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology. [PDF]
, 2014 Maladaptive plasticity can be defined as behavioral loss or even development of disease symptoms resulting from aberrant plasticity changes in the human brain.
Ahmed +58 more
core +2 more sources
Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments
Journal of Parkinson’s Disease, 2013 Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease (PD). Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor (DDCI ...
David Salat, Eduardo Tolosa
doaj +1 more source
Adrenal pheochromocytoma incidentally discovered in a patient with parkinsonism [PDF]
, 2015 To evaluate the diagnostic route of pheochromocytoma (PHEO) in a patient under dopaminergic treatment. A 70-year-old man with Parkinsonism and under treatment with levodopa and carbidopa came to our observation for evaluation of arterial hypertension and
Claudio Letizia +7 more
core +1 more source
New advances in amblyopia therapy I: Binocular therapies and pharmacologic augmentation [PDF]
, 2018 Amblyopia therapy options have traditionally been limited to penalisation of the non-amblyopic eye with either patching or pharmaceutical penalisation. Solid evidence, mostly from the Pediatric Eye Disease Investigator Group, has validated both number of
Culican, Susan M, Kraus, Courtney L
core +2 more sources
Extended Timed Up and Go assessment as a clinical indicator of cognitive state in Parkinson\u27s disease [PDF]
, 2017 Objective: To evaluate a modified extended Timed Up and Go (extended-TUG) assessment against a panel of validated clinical assessments, as an indicator of Parkinson’s disease (PD) severity and cognitive impairment. Methods: Eighty-seven participants with
Anderton, R +7 more
core +2 more sources
ADMET and DMPK, 2022 Levodopa is routinely co-administered with carbidopa in the management of Parkinson’s disease. Although the aforementioned combination therapy is effective, there may be fluctuating plasma levels of levodopa after oral administration.
Emelia Priscilla Imbeah +8 more
doaj +1 more source
Toward understanding ambulatory activity decline in Parkinson disease [PDF]
, 2015 BACKGROUND: Declining ambulatory activity represents an important facet of disablement in Parkinson disease (PD). OBJECTIVE: The primary study aim was to compare the 2-year trajectory of ambulatory activity decline with concurrently evolving facets of ...
Cavanaugh, James T. +5 more
core +1 more source
Structural MRI Correlates of Episodic Memory Processes in Parkinson's Disease Without Mild Cognitive Impairment. [PDF]
, 2015 BackgroundChanges in episodic memory are common early in Parkinson's disease (PD) and may be a risk factor for future cognitive decline. Although medial temporal lobe (MTL) memory and frontostriatal (FS) executive systems are thought to play different ...
Filoteo, J Vincent +3 more
core +2 more sources
Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations [PDF]
, 2014 In the recent years, the serotonin system has emerged as a key player in the induction of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease. In fact, serotonin neurons possess the enzymatic machinery able to convert exogenous l-DOPA
CARTA, MANOLO, TRONCI, ELISABETTA
core +1 more source